Pharma BD Deal Intelligence
Icagen's capabilities and core ion channel technology will help to further expand Pfizer's position in the pain relief disease area and our ability to develop…
Subsequent offering period expired September 19, 2011; 5,393,380 shares validly tendered which, with Pfizer's existing 1,067,015 shares, represented…
Pfizer divested the Icagen ion-channel platform to XRpro for $500K upfront plus up to $10.5M in milestones, four years after acquiring it for $56M, signaling…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Pfizer completed acquisition of ion-channel-drug discovery company Icagen ($6.00/share, ~$56M total). Note: small deal but strategically notable platform acquisition for Pfizer's Neusentis pain unit. Below $250M threshold but a notable platform deal.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Icagen, Inc. (this deal) | 2011 | $56M | 19 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2011 deals · Pfizer Inc. deals · Other deals